Pfizer at Cowen and Company 28th Annual Health Care Conference

1,114 views

Published on

Published in: Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,114
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
37
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Pfizer at Cowen and Company 28th Annual Health Care Conference

  1. 1. Our Path Forward Joe Feczko Senior Vice President & Chief Medical Officer
  2. 2. Forward-Looking Statements Our discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2007 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K. These reports are available on our website at www.pfizer.com in the quot;Investors—SEC Filingsquot; section.
  3. 3. The Forces at Work in Healthcare Today ty in ng Socie orld in ances gy Agi Adv ed W found Technolo Develop Pr o nd Risi ence a Sci ng M in D iddle eve lopi Class Info Reg Exp rmatio ions ng n l New osion & Med ia m Health US eris m ca Conso re Plans n su Co lidatin g Shift in Who “ Owns” the D ata Transp a Cost an rency of Affordability d Quali ty
  4. 4. 5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
  5. 5. 5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
  6. 6. Disease Area Priorities Invest to Win First or High Market High Best in Class Growth Unmet Need Oncology Pain Immunology / Inflammation Diabetes / Obesity Alzheimer’s Disease Schizophrenia
  7. 7. Today’s Phase 3 Portfolio axitinib – Pancreatic Cancer PD-332334 – GAD tremelimumab – Melanoma S,S-reboxetine – Fibromyalgia NMEs apixaban – VTE Prevention Zithromax/chloroquine – Malaria CP-945598 – Obesity New Indications apixaban – / Atrial Fibrillation
  8. 8. Projected 15–20 Phase 3 Starts 2008–2009 PF-3187207 PF-885706 – GERD PF-868554 PF-734200 – Glaucoma – HCV – Diabetes PF-299804 – Cancer CP-751871 PF-4194471 PF-4522625 PH-797804 – RA – Lung Cancer – HIV – Seasonal Flu NMEs IV sulopenem/Oral PF-4383119 CP-690550 UK-453061 sulopenem pro-drug – OA Pain – RA – HIV – Bacterial Infections PD-200390 – Insomnia apixaban – VTE PF-4383119 treatment & ACS – Chronic Pain axitinib – RCC & tremelimumab – CRC New Lung S,S-reboxetine – DPN Indications
  9. 9. Potential New Indications Expected To Drive Value Colorectal es nu ve Non Small Cell Lung Re Hepatocellular Carcinoma Breast Renal Cell Carcinoma & Gastrointestinal Stromal Tumor Time
  10. 10. Projected 15–20 Submissions 2010–2012 axitinib – Pancreatic Cancer Zithromax/chloroquine PF-734200 – Diabetes – Malaria S,S-reboxetine PD-200390 – Insomnia – Fibromyalgia PF-299804 – Cancer CP-751871 CP-945598 – Obesity PF-885706 – GERD – 3rd Line NSCLC NMEs PD-332334 – GAD PF-4522625 – Seasonal Flu PF-4383119 – OA Pain IV sulopenem / Oral PH-797804 – RA CP-690550 – RA sulopenem pro-drug PF-868554 – HCV – Bacterial Infections PF-4194471 – HIV UK-453061 – HIV axitinib – 1st Line S,S-reboxetine – DPN nd NSCLC & 2 Line RCC CP-690550 – Psoriasis apixaban – VTE PF-4383119 New Treatment, AF & Acute – Chronic Pain Coronary Syndrome Indications /
  11. 11. Steps to Improve Execution Focus Resources Identify Winners Early on Best Opportunities Improve Clinical Trial Design to Increase Improve Clinical Probability of a Positive Result Trial Execution Improve Cycle Times
  12. 12. Optimizing the Patent-Protected Portfolio
  13. 13. Lipitor: Maintaining Leadership Under Intense Competition 2008 Focus Lipitor 2007 Worldwide Sales Reinforce differentiation with U.S. Japan/Asia compelling body of clinical $7.8B $1.5B and outcomes evidence (-6%) (+7%) Drive activities targeted at Canada/ new and continuing patients Latin America/ Africa/ Maintain and leverage Middle East access $1.3B (+9%) Communicate data from Europe Lipitor’s strong clinical $3.0B program (-3%) Source: IMS MAT 4Q2007
  14. 14. Global Lyrica Forward Plan: Differentiate, Grow and Expand 2007 2008 + Core Indications Strengthen Core and Expand Restless Legs Syndrome Epilepsy Neuropathic Neuropathic Pain Pain GAD Post Op Epilepsy Pain Fibro Fibromyalgia GAD
  15. 15. Celebrex: Preserve Today & Set the Stage for Growth Strengthen Repair the Patient- Optimize Near-Term Understanding of Physician Dialogue Execution Efficacy & Safety Completion of Large Safety Studies Mid-Term (CONDOR, PRECISION)
  16. 16. Chantix: For Smokers Motivated to Quit 45M Smokers 25M Smokers in the U.S. Motivated to Quit Control Immature Takers Quitters 26% 25% 11.7M Desire to Quit Chantix Target MD/Rx- Defiant Dependent Smokers Quitters 20% 29% 13.0M Openness to Medical Intervention
  17. 17. Sutent: The Bedrock of Our Oncology Portfolio U.S. Potential New Indications mRCC Patient Share – 1st Line Expected to Drive Value 70% 60% CRC 53% 50% es nu 40% ve NSCLC Re HCC 30% Nexavar, 25% BC 20% cytokine, 11% 10% Torisel, 7% RCC / GIST Other, 5% 0% J FMAMJ J ASOND Time 2007 Source: ImpactRx
  18. 18. 5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
  19. 19. The Opportunity Global Pharmaceutical Sales ($ billions USD) $898 CAGR “Established” $576 11% Market Is: $523 Established Big Products $271 Fast growing (Near-Post LOE) Profitable Innovative 4% $375 $305 Products (Pre-LOE) 2006 2012 * Excludes Africa/Middle East market. Source: Datamonitor; EvaluatePharma; analyst reports.
  20. 20. The Market Is Not Homogenous, Three Distinct Market Segments Branded Emerging Markets Branded Traditional Markets IP-Driven Markets Source: Datamonitor; EvaluatePharma; analyst reports.
  21. 21. Our Competitive Advantage = Value Creation Leverage Strengths & Capabilities Our Product Portfolio Strong brand recognition Track record of proven efficacy Become a and safety World Leader Strong book of business today in in Product established products Enhancements and Reformulation Current portfolio about 4% of market Broad and deep commercial infrastructure around the world Pursue Excellence in Pharmaceutical Opportunities in “Niche” Markets Sciences Enhancing our value proposition State-of-the-art manufacturing processes and technologies Intensify Late Stage Lifecycle Planning
  22. 22. Our Goal – Outpace Market Growth Increase Emphasis on 1 Our Existing Portfolio Broaden the Geographic 2 Reach of Our Offerings Develop Partnerships 3 to Accelerate Our Pace
  23. 23. 5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
  24. 24. Right Geographies #2 Europe $13.3B 7.0% Share #1 U.S. #4 Africa/ #1 Japan #1 Asia Middle East $25.5B $3.7B 9.2% Share $2.6B $0.4B 6.4% Share 5.5% Share 5.8% Share #1 Latin America $1.4B 6.1% Share The Powerful Forces of Globalization Play to Our Strength Source: IMS MAT 4Q2007
  25. 25. Right Products New In-Line Established (glipizide) Extended Release Tablets Dynastat ® IV/IM (parecoxib sidico injectable)
  26. 26. The Emerging Asian Markets Opportunity Today 2012 Projection 2017 Projection 7–9% 6% 4% $47B $79B $111B Market Pfizer Source: Projections based upon IMS Market Prognosis March 2007 & Internal Analysis (excludes Japan, Australia, New Zealand)
  27. 27. Pfizer Well-Positioned and Investing for Growth in Emerging Asian Markets Asia Footprint People Significant 2007 Sales Programs to develop and Growth retain talent across markets #1 Rank in Asia Strong cadre of very experienced managers Regional support footprint in Hong Kong with cross- Three-quarters of talent local functional capabilities Regional management team Marketing and sales together for nearly 10 years infrastructure in all countries Reputation as a Good Partner, Corporate Citizen and Employer Source: IMS MAT 4Q2007 (excludes Japan, Australia, New Zealand)
  28. 28. Capturing Global Advantage – Building Out Today’s Presence R&D Manufacturing $300 million investment in Manufacturing sites and experience South Korea across Asia R&D facility in China First trigeneration power plant in Singapore – an environmental- Establish incubators to aid Asian friendly energy source start-ups New Asia R&D head based out of Shanghai and reporting to M. Mackay Business Development Asia strategy founded on organic, internally driven growth Business development opportunities also exist to supplement growth and hedge against risk New head of regional and local business development based out of Hong Kong
  29. 29. Asia Strategy Reinforce market leadership in the region, grow market share from 4% to 7–9% #1 pharma company in China, grow market share from ~2% to ~8–11% Goals Drive Korea to $1 billion business Top 3 in fast-growing Asian oncology market Capture global advantage
  30. 30. Right Products Right Business Models Right Geographies
  31. 31. 5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
  32. 32. Our Path Forward Joe Feczko Senior Vice President & Chief Medical Officer

×